Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 6, 2014, Pages 1037-1046

  Van Blarigan, Erin L ^a   Ma, Jing ^c,d   Kenfield, Stacey A ^b   Stampfer, Meir J ^c,d   Sesso, Howard D ^c,d   Giovannucci, Edward L ^c,d   Witte, John S ^a,b   Erdman Jr , John W ^e   Chan, June M ^a,b   Penney, Kathryn L ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; CATALASE; GAMMA TOCOPHEROL; GLUTATHIONE PEROXIDASE 1; LYCOPENE; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; CAT PROTEIN, HUMAN; GLUTATHIONE PEROXIDASE; MANGANESE SUPEROXIDE DISMUTASE; PHOSPHOLIPID-HYDROPEROXIDE GLUTATHIONE PEROXIDASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; ENZYME BLOOD LEVEL; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; COHORT ANALYSIS; DISEASE COURSE; ENZYMOLOGY; GENETICS; GENOTYPE; MOLECULAR EPIDEMIOLOGY; MORTALITY; PROSPECTIVE STUDY; PROSTATE TUMOR; SURVIVAL ANALYSIS;

AGED; ANTIOXIDANTS; CATALASE; COHORT STUDIES; DISEASE PROGRESSION; GENOTYPE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MOLECULAR EPIDEMIOLOGY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS;

EID: 84903380277     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0670     Document Type: Article

References (32)

1. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, et al. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 2007;86:672-81. (Pubitemid 47435834)
2. Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005;135:2030S-1S. (Pubitemid 41099768)
3. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. J Clin Oncol 2005;23:8152-60. (Pubitemid 46211548)
4. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995;62:1427S-30S.
5. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 1999;59:1225-30. (Pubitemid 29136251)
6. Helzlsouer KJ, Huang HY, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23. (Pubitemid 32045898)
7. Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003;157:335-44. (Pubitemid 36193936)
8. Virtamo J, Pietinen P, Huttunen JK, Korhonen P, Malila N, Virtanen MJ, et al. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA 2003;290:476-85. (Pubitemid 37430501)
9. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, et al. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005;97:396-9. (Pubitemid 40425958)
10. Watters JL, Gail MH, Weinstein SJ, Virtamo J, Albanes D. Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. Cancer Res 2009;69:3833-41.
11. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011;306:1549-56.
12. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8. (Pubitemid 47328718)
13. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, et al. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 2011;107:126-34.
14. Mao C, Qiu LX, Zhan P, Xue K, Ding H, Du FB, et al. MnSOD Val16Ala polymorphism and prostate cancer susceptibility: a meta-analysis involving 8,962 subjects. J Cancer Res Clin Oncol 2010;136:975-9.
15. Chan JM, Stampfer MJ, Ma J, Rimm EB, Willett WC, Giovannucci EL. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol Biomarkers Prev 1999;8:893-9. (Pubitemid 29508725)
16. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-504. (Pubitemid 40490163)
17. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Wu K, Erdman JW Jr, et al. Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk. Carcinogenesis 2008;29:2335-40.
18. Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005;16:255-62. (Pubitemid 40897844)
19. Wu K, Erdman JW Jr, Schwartz SJ, Platz EA, Leitzmann M, Clinton SK, et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2004;13:260-9. (Pubitemid 38222558)
20. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol 1984;119:837-9. (Pubitemid 14142821)
21. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-6. (Pubitemid 28160635)
22. Weinstein SJ, Wright ME, Lawson KA, Snyder K, Mannisto S, Taylor PR, et al. Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:1253-9. (Pubitemid 46984967)
23. Weinstein SJ, Peters U, Ahn J, Friesen MD, Riboli E, Hayes RB, et al. Serum alpha-tocopherol and gamma-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study. PLoS ONE 2012;7:e40204.
24. Wu K, Schwartz SJ, Platz EA, Clinton SK, Erdman JWJr, Ferruzzi MG, et al. Variations in plasma lycopene and specific isomers over time in a cohort of U.S. men. J Nutr 2003;133:1930-6. (Pubitemid 36666537)
25. Willett WC. Nutritional epidemiology. 2nd ed. New York: Oxford University Press; 1998.
26. Stark JR, Wiklund F, Gronberg H, Schumacher F, Sinnott JA, Stampfer MJ, et al. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18:1859-63.
27. Mefford J, Witte JS. The covariate's dilemma. PLoS Genet 2012;8:e1003096.
28. Gill JK, Franke AA, Steven Morris J, Cooney RV, Wilkens LR, Le Marchand L, et al. Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. Cancer Causes Control 2009;20:1161-71.
29. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, Neal DE, et al. Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control 2012;23:1865-73.
30. Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, et al. Variation in selenoenzyme genes and prostate cancer risk and survival. Prostate 2013;73:734-42.
31. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol 2009;27:3577-83.
32. Comstock GW, Burke AE, Hoffman SC, Norkus EP, Gross M, Helzlsouer KJ. The repeatability of serum carotenoid, retinoid, and tocopherol concentrations in specimens of blood collected 15 years apart. Cancer Epidemiol Biomarkers Prev 2001;10:65-8. (Pubitemid 32106046)